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Abstract
Background: Lead is a pervasive neurotoxicant that has been associated with poorer cognitive, behavioral, and
motor outcomes in children. The effects of lead on sensory function have not been well characterized. The aim of
this study was to assess the effects of prenatal lead exposure on infant sensory function, as measured by auditory
brainstem response (ABR) and grating visual acuity (VA).
Methods: Lead was measured in maternal blood in mid- and late-pregnancy (mean gestational age = 15.5 and 39.
0 weeks, respectively) and umbilical cord blood in a cohort of full-term infants in rural northeastern China. ABR
latencies (peaks I, III, V) were measured in newborns during unsedated sleep (n = 315). The ABR central-to-peripheral
(C-P) ratio was calculated as the ratio between the III-V and I-III interpeak intervals. VA was measured in 6-week-olds
using Teller Acuity Cards (n = 1019) and assigned as the narrowest grid the infant fixated on. Multivariate linear
regression was used to evaluate relationships between tertiles of mid-pregnancy, late-pregnancy, or cord lead and
newborn ABR or 6-week VA.
Results: Higher late-pregnancy lead levels were associated with higher ABR C-P ratios and lower VA. In
covariate-adjusted analyses, mean C-P ratios were 4.6 and 3.2 % higher in infants whose mothers had lead > 3.
8 μg/dL and lead = 2–3.8 μg/dL, respectively, than for infants whose mothers had lead < 2 μg/dL (p-trend =0.002).
In adjusted analyses for VA, mean scores were 8.5 and 7.2 % lower for maternal lead > 3.8 μg/dL and lead = 2–3.
8 μg/dL, respectively, compared to lead < 2 μg/dL (p-trend =0.009).
Conclusion: Auditory and visual systems maturation appears delayed in infants with higher prenatal lead exposure
during late-pregnancy, even at relatively low levels. Both systems start myelinating in late gestation and mature
rapidly in infancy. Higher ABR C-P ratio and lower grating VA scores suggest effects of low-level lead exposure on
sensory system myelination.
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Background
Lead is a naturally occurring element that has numerous
industrial uses. Despite lead abatement successes in
much of the developed world through the phasing-out
of leaded paints and gasoline, lead remains a large global
public health problem [1]. In the U.S. it can still be found
in aviation gas, ammunition, and lead-acid car batteries.
Many older houses still have leaded paint and pipes. In
developing or transitional countries, such as China, it is
still used in decorative paints and glazes, children’s toys,
gasoline, cosmetics, and much more [2]. Lead’s widespread
use has resulted in environmental contamination and hu-
man exposure via multiple pathways. Non-occupational
exposure most commonly occurs from ingestion of lead-
contaminated dust, water, or food [3].
Pediatric lead exposure has been a major public health
concern for decades, because lead is highly and select-
ively toxic to the central nervous system (CNS). Many
neurodevelopmental and neurobehavioral effects of child-
hood and fetal lead exposure have been documented.
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IQ and cognitive test scores, more behavioral abnormalities,
decrements of executive and motor functions, and altered
memory and language, inattention, aggression, and other
neurological deficits [4–6]. The fetus is especially at risk,
since lead has the ability to cross the placental and blood
brain barriers [3, 4]. Additionally, maternal bone turnover
during pregnancy may release lead from bone, thereby fur-
ther exposing the developing fetus [7]. During the fetal
period, the brain is undergoing rapid growth and matur-
ation, making it highly susceptible to potentially long-term
effects of lead exposure. Given this rapid development, the
timing of exposure is of particular importance [8–10],
though many studies are limited to only one measurement,
which may not accurately represent exposure at sensitive
stages.
Despite a growing body of knowledge about the cognitive,
behavioral, and motor effects of pediatric lead exposure,
much less is known about how lead may affect sensory
functions, such as visual and auditory function. Visual and
auditory system development in infancy provides the foun-
dation for many learning processes in infancy and child-
hood, such as development of communication, language,
and reading skills [11, 12]. Prenatal lead exposure may alter
the timing of sensory systems myelination in the brain,
potentially leading to detrimental long-term effects on
learning or other cognitive functions later in childhood.
Epidemiological studies have examined childhood lead
exposure and auditory brainstem response with inconsist-
ent findings [13–23], and only three looked at prenatal
lead exposure [18, 21, 22]. We were unable to identify any
human studies that investigated prenatal lead exposure
and grating visual acuity.
Therefore, we assessed the impact of prenatal lead ex-
posure at three different time points during pregnancy
on infant sensory function, as measured by auditory
brainstem response (ABR) and grating visual acuity (VA).
These measures provide non-invasive ways of assessing
auditory and visual system maturation and, indirectly,




All study protocols and procedures were approved by
the appropriate ethics committees of both the University
of Michigan and Peking University First Hospital.
Signed, informed consent was obtained from parents fol-
lowing a thorough explanation of all procedures.
Study sample
Study participants were healthy pregnant women, aged
18 years or older, with a singleton pregnancy and no
major complications, who resided in Sanhe County, Hebei
Province, China. Women were recruited at their initial
prenatal visit at Sanhe City Maternity and Child Health
Institute, from November 2009 to November 2011, as part
of a study of early iron deficiency and neurodevelopment.
Lead
Whole blood for lead analysis was collected from the
mothers at two time points during pregnancy, at enroll-
ment and at or near term, and in cord blood at birth.
Maternal blood (5 mL) was obtained by venipuncture
and cord blood samples (5 mL) by sterile needle puncture
immediately after cord clamping. Blood was collected in
trace-metal free tubes treated with EDTA and stored
at −20 C until analysis.
Whole blood samples (40 μL) were analyzed for lead
using atomic absorption spectrometry (AAS) using a
BH2100S tungsten atomizer atomic absorption spec-
trometer (Beijing Bohui Innovation Technology Co.,
Ltd., Beijing, China) in the clinical laboratory of the
Pediatrics department of Peking University First Hospital
(Beijing, China). Blood samples were observed for signs of
clotting prior to analysis and none were detected. Blood
samples were measured once, but if lead was determined
to be >10 μg/dL, samples were re-run and the average of
the two measurements was used. The limit of detection
(LOD) of the method was 1.0 μg/dL, which was calculated
as 3 times the standard deviation of the blank. The limit of
quantification (LOQ) for the method was 2.0 μg/dL.
The lab participates in the National System of External
Assessment of the Quality of Results, an external quality
assurance program conducted by China’s National Center
for Clinical Laboratories (NCCL). Internal quality control
included running blanks and certified reference materials
(Chinese national standard: GBW (E) 09003336 [Beijing
Bohui Innovation Technology Co., Ltd., Beijing, China] at
concentrations of 5, 10, 30 μg/dL) in parallel with study
samples (every 10 samples) for each batch. Quality control
analysis yielded coefficients of variation ranging from 8.2
to 12.1 %.
Based on the distributions of the blood lead concentra-
tions, and the relatively high LOQ (2 μg/L), we categorized
lead roughly into tertiles for analysis (<2, 2-3.8, >3.8 μg/dL
for pregnancy lead time points and <2, 2-3.2, >3.2 μg/dL
for cord lead).
Auditory Brainstem Response (ABR)
ABR, also known as brainstem auditory evoked potentials
(BAEPs), measures the brain’s electrical activity following
an auditory stimulus by quantifying the progressive activa-
tion of different points along the auditory pathway. ABRs
in infants consist of three prominent peaks, corresponding
to distal cochlear nerve activation (wave I), activation of
the cochlear nuclei (wave III), and the nucleus of the
lateral lemniscus (wave V) [24, 25]. The rapid decrease
in ABR interpeak latencies (and thus, increased speed
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of transmission) observed during early development in
infancy is directly attributable to increasing myelination
of the auditory pathways in the infant brain [26, 27].
Less decrease in the interpeak latencies in the central
(III-V interval), relative to the more peripheral compo-
nents (I-III interval), of the auditory pathway is considered
to be an indicator of impaired myelination [28].
ABR was measured in a subset of 391 newborns (average
two days old) during unsedated sleep using a Biologic Navi-
gator (Bio-Logic Systems Corp., Mundelein, IL)/Traveler
evoked potential system. Infants underwent ABR testing
with a standard hearing screening protocol at 30 dB and a
second forward-masking protocol with varied intervals (8,
16, or 32 ms) between pairs of monophasic clicks at 80 dB.
Stimuli for the hearing screening test were a series of
square wave rarefaction clicks with a duration of 100 μs,
delivered to each ear by means of insert transducers at a
rate of 31.3/sec and intensity of 30 dB, nHL. ABR was
recorded by surface silver/silver chloride electrodes at-
tached to infant's foreheads using adhesive tabs (midline
below the hairline [non-inverting] and the mastoid on
each side [ipsilateral as inverting; contralateral as ground
electrode]. The impedance was below 10 kΩ for all re-
cordings. The data acquisition program rejected traces
contaminated by high-amplitude artifacts (voltage greater
than ± 23.80 μV). 1300 sweeps were averaged to complete
each run, and two consecutive averages were obtained for
each ear. The right and left ears were then averaged to ob-
tain a single measurement from each subject. The EEG
was amplified and band-pass filtered from 30 to 1500 Hz.
Infants who passed the hearing screening test contin-
ued on to the forward-masking protocol, presented by
using a pair of 100 μs click stimuli at 80 dB, nHL. The
time between the “masker” and “probe” clicks was varied
with intervals of 8, 16, and 32 ms and presented in
blocks, beginning with the 32 ms condition, followed by
the 16 ms and 8 ms conditions. Responses to the second
(probe) stimulus were measured (wave I, III, and V laten-
cies). The pairs of click stimuli were delivered to each ear
by insert transducers with a presentation rate of 11.7/sec.
The recording epoch was 74.67 ms. For each condition,
two replications were added, yielding an average waveform
for 2600 sweeps per ear. Individual waves for each condi-
tion were identified and marked by trained technicians.
Values for the right and left ears were averaged so that
each infant was assigned a single value for each condition,
derived from a total of 5200 sweeps.
Latencies for waves I, III, and V were used to calculate
the central-to-peripheral (C-P ratio), which is the ratio
between the III-V and I-III interpeak intervals ([latency
V- latency III]/[latency III- latency I]). Of the 391 neo-
nates with ABR testing, maternal lead was available for
343 at mid-pregnancy and 362 at late-pregnancy; cord
blood lead was available for 321.
Grating Visual Acuity (VA)
Visual acuity improves throughout in infancy and child-
hood as the visual pathway becomes myelinated [29].
Grating VA was measured in six-week-old infants using
a preferential looking test procedure with Teller Acuity
Cards. Luminance of the ambient lighting was kept con-
stant at 85 candelas/m2 from overhead diffuse fluorescent
lights. VA testing was performed by three well-trained ex-
aminers who were blinded to the infants’ lead exposure
status. Infants were held upright by their mothers facing a
Teller Acuity Test stage placed 38 cm away. Examiners
presented infants with a series of mounted gray prints,
with black and white vertical gratings to one side and a
blank to the other side, through a rectangular opening in
the stage. Gratings ranged from coarse to fine (0.44–27 cy-
cles/degree) and cards were of approximately 35 % reflect-
ance. Cards were presented in order of lower to higher
spatial frequencies (wider to narrower gratings) and so
gratings were located on both the left and right sides of
the print for each frequency. Examiners watched the
child’s eye movements through a small central aperture in
the stage and decided, based on the infant’s looking be-
havior, which cards could be seen by the infant. If look-
ing responses were unclear, examiners would repeat the
presentation several times until a confident judgment
could be made about whether the grating could be
seen. Acuity was estimated as the spatial frequency of
the finest grating that the infant could resolve, as indicated
by the child’s consistent looking toward the location of
that grating upon repeated presentations of the card. If an
examiner had low confidence in his or her acuity estimate,
a second examiner, blinded to the results of the first test-
ing, would re-test the infant. If the infant’s condition was
determined to be unsuitable for testing that day, parents
were asked to return for testing another day. Grating VA
testing was performed for 1148 infants. Of these, maternal
lead was available for 1038 at mid-pregnancy and 1058 at
late-pregnancy, and cord blood lead was available for 949.
Covariates
Sex, gestational age, birth weight, and head circumference
were all recorded at the time of birth. Gestational age was
estimated from last menstrual period. Cord blood iron sta-
tus was defined using serum ferritin, which was measured
by chemiluminescent immunoassay (IMMULITE, Diag-
nostic Products) and categorized into deficient or normal
(≤75 and >75 μg/L). Serum ferritin values >370 μg/L were
excluded due to possibility of inflammation or infection.
Statistical analysis
SAS version 9.3 (SAS Institute, Cary, NC) was used for
all analyses. Descriptive statistics, frequencies, and corre-
lations for all variables of interest were examined. Gen-
eralized Linear Models (GLM) were used to evaluate
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associations between categories of prenatal blood lead
exposure at the three time points and either newborn
ABR C-P ratio (for 32, 16, and 8 ms conditions) or
six-week grating VA scores. Crude, partially adjusted
(for sex, age at testing, cord ferritin), and fully adjusted
(additional adjustments for birth weight and head circum-
ference) models were analyzed for all relationships of inter-
est. Sensitivity analyses excluding infants with low serum
ferritin were also investigated to test the strength of the re-
lationships between lead exposure and sensory function
without the possible confounding influence of iron defi-
ciency. To address the possibility that the few extremely
high lead levels observed may have been due to laboratory
contamination or blood clotting, additional sensitivity ana-
lyses excluding those high lead levels were also completed.
Results
Distributions of the prenatal lead concentrations can be
found in Table 1. Late-pregnancy lead and cord lead
concentrations were significantly correlated; Spearman
rank ρ = 0.43, p < 0.0001 and ρ = 0.30, p < 0.0001 for the
infants with ABR or VA samples, respectively. Mid- and
late-pregnancy lead concentrations were not significantly
correlated, nor were mid-pregnancy and cord lead con-
centrations. Full characteristics of the study sample are
shown in Table 2.
Crude, semi-adjusted, and adjusted GLM model results
are shown in Table 3. Maternal lead in late-pregnancy was
significantly associated with both tests of infant sensory
function.
At the 32 ms masker delay condition, late-pregnancy
lead levels were significantly positively associated with
newborn ABR C-P ratios, with and without adjustment
for covariates. In adjusted analyses, mean C-P ratios
were 4.6 % higher (95 % CI: 1.8–7.4 %) and 3.2 % higher
(95 % CI: 0–5.9 %), for infants whose mothers had late-
pregnancy lead >3.8 μg/dL and lead =2–3.8 μg/dL, respect-
ively, than for infants whose mothers had late-pregnancy
lead <2 μg/dL (p-trend =0.002) (Fig. 1). ABR C-P ratios
were not associated with mid-pregnancy or cord lead levels.
Findings for the 8 ms and 16 ms conditions did not reach
statistical significance and are presented in Additional file 1:
Table S1. To confirm that the ABR C-P findings were, in
fact, due to longer latencies in the inner portions of the
auditory pathway, as opposed to shorter latencies in the
outer portions of the pathway, we analyzed interpeak inter-
vals I-III and III-V individually with prenatal lead level. The
results confirmed that the higher C-P ratios were primarily
due to longer wave III-V interpeak intervals (Additional file
1: Table S2).
Grating VA scores were lower with higher late-pregnancy
lead level. In adjusted analyses, mean VA scores were 8.5 %
lower (95 % CI: 2.4–14.7 %) and 7.2 % lower (95 % CI: 1.1–
13.3 %), for infants whose mothers had late-pregnancy
lead >3.8 μg/dL and lead =2–3.8 μg/dL, respectively, than
for infants whose mothers had late-pregnancy lead <2 μg/
dL (p-trend =0.009) (Fig. 1). Similar to the ABR results, no
statistically significant associations were observed for VA
and levels of mid-pregnancy lead or cord lead.
Sensitivity analyses, with low ferritin infants excluded,
confirmed the ABR results. C-P ratios were significantly
higher in infants whose mothers had higher blood lead
levels late in pregnancy, with similar trends, statistical
significance, and directions of association as were seen
with the full data set; adjusted β (95 % CI) =0.06 (0.03–
0.09), 0.04 (0.01–0.08) for infants whose mothers had
late-pregnancy lead >3.8 μg/dL and lead =2–3.8 μg/dL,
respectively, compared to infants whose mothers had
late-pregnancy lead <2 μg/dL (p-trend < 0.001). The VA
results were attenuated with the exclusion of low ferritin
infants, though overall trends and directions of associa-
tions remained consistent; adjusted β (95 % CI) = −0.07
(−0.14–0.01), −0.05 (−0.13–0.02) for infants whose mothers
had late-pregnancy lead >3.8 μg/dL and lead =2–3.8 μg/dL,
respectively, compared to infants whose mothers had late-
pregnancy lead <2 μg/dL (p-trend = 0.096).
Sensitivity analyses excluding the extremely high lead
levels led to the deletion of 8 values (1 from the ABR/
late-maternal lead analysis, 1 from the ABR/cord lead
analysis, 6 from the VA/late-maternal lead analysis). Ex-
clusion of these values had no notable effect on the re-
sults. ABR C-P ratios remained significantly higher in
infants whose mothers had higher blood lead levels late
in pregnancy, with similar trends, statistical significance,
Table 1 Distribution of prenatal lead concentrations in the study sample at three time points (μg/dL)
Infants with Newborn ABR Data Infants with 6-Wk Grating VA Data
Lead exposure N GM (SD)a Percentile N GM (SD)a Percentile
50th 75th 90th 95th Max. 50th 75th 90th 95th Max.
Mid-pregnancyb 343 2.4 (2.5) 2.9 4.4 5.5 6.4 9.0 1038 2.4 (2.6) 2.9 4.4 6.3 8.2 19.0
Late-pregnancyc 362 2.7 (2.3) 3.0 4.5 6.2 7.2 76.0 1058 2.9 (2.2) 3.3 4.7 6.4 7.7 69.8
Cordd 321 <LOQ <LOQ 3.2 5.0 5.7 24.7 949 <LOQ 2.1 3.3 4.7 5.5 13.5
aGM geometric mean, SD standard deviation
bMean (SD) gestational age at mid-pregnancy visit is 15.7 (2.2) weeks for ABR subset and 15.5 (1.9) weeks for VA data
cMean (SD) gestational age at late-pregnancy visit is 38.8 (1.3) weeks for ABR subset and 39.3 (1.3) weeks for VA data
dMean (SD) gestational age at birth is 39.2 (1.1) weeks for ABR subset and 39.7 (1.1) weeks for VA data
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Table 2 Study sample characteristics





Gestational age (wks) at mid-pregnancy visit 353 15.0 (13.0, 19.0) 1054 15.0 (13.0, 19.0)
Gestational age (wks) at late-pregnancy visit 352 39.0 (37.0, 41.0) 1054 39.4 (36.9, 41.3)
Gestational age (wks) at birth 353 39.0 (37.0, 41.0) 1058 39.7 (37.9, 41.4)
Birth weight (g) 361 3400 (2850, 4100) 1054 3400 (2750, 4000)
Head circ. (cm) 361 34.1 (31.9, 36.0) 1030 34.1 (32.0, 36.0)
Age at testing (days) 362 2.2 (1, 4) 1058 43 (41, 89)
N (%) N (%)
Sex (male) 350 183 (52.3) 1053 555 (52.5)
Low cord ferritin 360 99 (27.5) 1055 298 (28.3)
Table 3 GLM results for associations between prenatal lead and infant ABR C-P ratioa and grating VA
Crude Semi-adjustedb Fully-adjustedc
N β (95 % CI)d N β (95 % CI)d N β (95 % CI)d
ABR C-P ratio
Mid-pregnancy lead 304 292 292
High (>3.8 μg/dL) 0.02 (−0.00–0.05)† 0.02 (−0.01–0.05) 0.02 (−0.01–0.05)
Med. (2–3.8 μg/dL) 0.02 (−0.01–0.05) 0.02 (−0.01–0.05) 0.02 (−0.01–0.05)
Low (<2 μg/dL); Reference p-trend = 0.09† p-trend = 0.12 p-trend = 0.13
Late-pregnancy lead 315 304 304
High (>3.8 μg/dL) 0.04 (0.02–0.07)** 0.05 (0.02–0.08)*** 0.05 (0.02–0.07)**
Med. (2–3.8 μg/dL) 0.03 (0.00–0.05)† 0.03 (0.01–0.06)* 0.03 (0.00–0.06)**
Low (<2 μg/dL); Reference p-trend = 0.002** p-trend < 0.001*** p-trend = 0.002**
Cord lead 277 267 267
High (>3.2 μg/dL) 0.00 (−0.03–0.03) 0.00 (−0.02–0.03) 0.00 (−0.03–0.03)
Med. (2–3.2 μg/dL) −0.00 (−0.03–0.02) −0.00 (−0.03–0.03) −0.00 (−0.03–0.03)
Low (<2 μg/dL); Reference p-trend = 0.99 p-trend = 0.81 p-trend = 0.88
Grating VA
Mid-pregnancy lead 1000 990 961
High (>3.8 μg/dL) 0.00 (−0.06–0.08) −0.03 (−0.09–0.03) −0.02 (−0.08–0.04)
Med. (2–3.8 μg/dL) 0.02 (−0.05–0.09) 0.02 (−0.04–0.08) 0.03 (−0.03–0.09)
Low (<2 μg/dL); Reference p-trend = 0.90 p-trend = 0.36 p-trend = 0.52
Late-pregnancy lead 1019 1016 985
High (>3.8 μg/dL) −0.12 (−0.19–0.05)** −0.08 (−0.14–0.02)* −0.09 (−0.15–0.02)**
Med. (2–3.8 μg/dL) −0.08 (−0.16–0.01)* −0.07 (−0.13–0.01)* −0.07 (−0.13–0.01)*
Low (<2 μg/dL); Reference p-trend = 0.002** p-trend = 0.01* p-trend = 0.009**
Cord lead 916 916 888
High (>3.2 μg/dL) −0.02 (−0.10–0.05) −0.03 (−0.09–0.03) −0.03 (−0.10–0.03)
Med. (2–3.2 μg/dL) −0.05 (−0.12–0.02) −0.05 (−0.11–0.01)† −0.05 (−0.11–0.01)†
Low (<2 μg/dL); Reference p-trend = 0.45 p-trend = 0.25 p-trend = 0.22
a32 ms masking condition
bAdjusted for sex, age at testing, cord blood iron status
cAdjusted for sex, age at testing, cord blood iron status, gestational age, birth weight, head circumference
dEffect estimates are reported in cycles/degree for VA; ABR C-P ratio has no units (ms/ms)
† p < 0.10; * p < 0.05; ** p < 0.01; *** p < 0.001
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and directions of association as were seen with the full
data set; adjusted β (95 % CI) =0.05 (0.02–0.07), 0.03
(0.00–0.06) for infants whose mothers had late-pregnancy
lead >3.8 μg/dL and lead =2–3.8 μg/dL, respectively,
compared to infants whose mothers had late-pregnancy
lead <2 μg/dL (p-trend = 0.002). VA scores also remained
significantly higher in infants whose mothers had higher
blood lead levels late in pregnancy, with similar trends, stat-
istical significance, and directions of association as were
seen with the full data set; adjusted β (95 % CI) = −0.09
(−0.15–0.03), −0.07 (−0.13–0.01) for infants whose mothers
had late-pregnancy lead >3.8 μg/dL and lead =2–3.8 μg/dL,
respectively, compared to infants whose mothers had late-
pregnancy lead <2 μg/dL (p-trend = 0.008).
Discussion
Despite the relatively low lead levels in our sample,
maternal blood lead at or near term was significantly
associated with deficits in auditory and visual sensory
outcomes in early infancy. Significant associations
were not observed for lead levels at time of recruitment
(mid-pregnancy) or cord lead levels. Neonates (average
two days old) whose mothers had higher lead levels in late
pregnancy were more likely to have higher C-P ratios on
ABR testing, consistent with impaired myelination of the
innermost portions of the auditory pathway. Neonates
whose mothers had higher lead levels in late pregnancy
were more likely to have lower grating VA scores, consist-
ent with impaired myelination of the visual tract. Sensitiv-
ity analyses excluding infants with low iron stores at birth
confirmed the robustness of the ABR results but showed
some attenuation of the findings for grating VA. Add-
itional sensitivity analyses with extremely high blood
levels excluded, in case of laboratory contamination or
blood clotting, had no effect on either the ABR or the
VA findings.
Given that the late-pregnancy blood sample was col-
lected very near term, it was somewhat unexpected that
the cord blood lead results were not more similar to the
late-pregnancy lead results. We believe this discrepancy
is likely a result of the large number of cord lead sam-
ples that were < LOQ (51 % for the ABR sample and
45 % for the VA sample). While it is quite common for
lead in cord blood to be lower than maternal blood lead
taken in late pregnancy or at birth [9, 30, 31], the rela-
tively low lead levels in our sample coupled with the
relatively high LOQ resulted in a large reference group
and smaller medium and high lead exposure groups with
which to compare it. This may have limited our ability
to assess the effect of cord lead level on our outcomes of
interest.
Little is known about the effects of prenatal lead ex-
posure on auditory function in humans. We identified
three other studies that looked at prenatal lead exposure
and auditory-related outcomes in children. Dietrich and
colleagues found that higher prenatal blood lead levels,
measured at the first prenatal visit, were associated with
poorer central auditory processing at five years, as mea-
sured by the Filtered Word Subtest (FWS) of the SCAN,
a screening test for auditory processing disorders [18].
Two additional studies by Rothenberg et al. found that
maternal blood lead at 20 weeks was associated with in-
creased ABR interpeak intervals in one-month-olds
(wave I-III) and five-to-seven-year-olds (waves I-III and
III-V) [21, 22]. Prenatal lead levels in these studies aver-
aged three to four times higher than in our study
(8.2 μg/dL [18] and 8.1 μg/dL [21, 22] versus 2.4 and
2.7 μg/dL).
Fig. 1 Late-pregnancy maternal lead level and six-week grating VA and newborn ABR C-P ratioa. aVA and ABR C-P have different scales; Effect estimates
are reported in cycles/degree for VA; ABR C-P ratio has no units (ms/ms)
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Other studies have considered associations between
blood lead levels in early childhood and various mea-
sures of auditory function. Higher concurrent blood lead
levels were associated with longer ABR peak latencies in
children aged one to six years [13], and longer interpeak
intervals at 12 and 48 months [22]. Blood lead levels in
1- to 5-year-olds were significantly positively associated
with ABR wave latencies at a five-year follow-up [17].
Additionally, both neonatal blood lead at 10 days and
average blood lead concentrations (taken quarterly over
the first five years of life) had negative effects on audi-
tory processing in five-year-olds [18]. Thus, higher blood
lead levels in young children seem to be consistently as-
sociated with auditory deficits.
Blood lead levels in older children may also be associ-
ated with deficits in auditory function, though the results
are mixed. Higher concurrent blood lead levels were as-
sociated with increased interpeak intervals [32], wave I
latencies [23], and hearing thresholds [23, 33, 34]. How-
ever other studies found no association between concur-
rent blood lead and ABRs in older children [14–17, 22].
Two studies of multi-age cohorts, ranging from toddlers
to teenagers, without age-specific analyses, also found no
association between concurrent blood lead and auditory
function [19, 20].
Studies in monkeys have yielded similar results. Early
life or gestational lead exposure produced long-term
changes in ABR latencies, but later exposure had less ef-
fect. Rhesus monkeys exposed to very high lead levels
(55–122 μg/dL) during gestation and shortly after birth
had significantly longer ABR wave latencies, even after
cessation of exposure [35, 36]. In contrast, monkeys who
were exposed to high levels of lead postnatally, during
the first two years of life, did not show reductions in
auditory function, as measured by tympanometry, oto-
acoustic emissions, and ABR [37].
For visual function, there are even fewer studies in
humans. To our knowledge this is the first study to
examine prenatal lead exposure and grating visual acuity.
A few other studies have examined prenatal or childhood
lead exposure and other measures of visual function. One
study found increased a- and b-wave amplitudes of sco-
topic electroretinograms of 7- to 10-year-olds with higher
first trimester prenatal lead exposure, indicating that lead
may target the developing retina [38]. Another study
examined concurrent lead exposure and visual function
in 6- to 12-year-old children, using pattern reversal vis-
ual evoked potentials (VEP), and found no significant
effects [17]. However, the same study found that blood
lead levels five years prior may be associated with VEP
measures [17]. A third study reported significant negative
correlations between visual acuity and concurrent blood
lead in 6-year-olds [39]. The same study also showed that
visual contrast sensitivity was an important confounder in
models of blood lead and neurobehavioral tests [39]. Very
high blood lead levels in childhood have also been associ-
ated with night blindness in children [40, 41].
Rhesus monkeys exposed to high levels of lead (24–
37 μg/dL) both pre- and postnatally had lower ampli-
tudes and longer latencies following flash VEP [42], as
well as increased b-wave amplitudes for ERG [42, 43].
Monkeys exposed to high postnatal lead exposure
showed deficits in temporal visual function [44], while
another study found no effect of postnatal lead on
photopic spatial acuity development [45].
Therefore, the available human and non-human primate
studies suggest that lead can have negative effects on
auditory and visual function, especially when exposure
occurs prenatally or in early infancy. The brain is rapidly
developing during these periods, and environmental in-
sults occurring during them have the potential for long-
lasting effects. Our study supports and augments this body
of work by providing evidence of deficits in auditory and
visual functioning at much lower lead levels than previ-
ously investigated.
One mechanism by which lead may contribute to audi-
tory and visual system deficits is through the targeting of
oligodendrocytes. Oligodendrocytes are responsible for syn-
thesizing and maintaining myelin in the central nervous
system (CNS). Myelin sheaths surround neuronal axons
and facilitate transmission of nerve impulses. In vitro
experiments show that oligodendrocytes may be the
most lead-sensitive cell type in the brain [46] and that lead,
at high exposure levels, may even lead to de-myelination of
neuronal axons [47]. Dose-response studies in rats further
report that early oligodendrocyte progenitor cells are more
sensitive to lead than mature oligodendrocytes and that
exposure to lead during development can delay their
differentiation [48]. Thus, lead exposure may impact
brain development by interfering with the timing of
oligodendrocyte progenitor maturation [48]. Addition-
ally, exposure to a metals mixture (lead, arsenic, and
cadmium) in developing rats (in utero to two months
post-weaning) led to a reduction in myelin thickness and
axon-density in the optic nerve and enhanced apoptosis of
cells containing myelin-related proteins [49].
Our ABR results support the hypothesis that lead inter-
feres with myelination. The C-P ratio indicates whether
nerve conduction and synaptic transmission are different
in the central versus distal components of the auditory
pathway [27]. Since the process of myelination is centri-
petal, the C-P ratio is expected to be higher with a dis-
order of myelination [27]. We observed higher C-P ratios
with higher maternal lead levels late in pregnancy but not
at mid-pregnancy. Myelination of sensory tracts in the
fetal brain does not begin until late in pregnancy [29, 50].
Our results thus make sense in terms of the time course
of auditory system myelination in fetal development.
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A plausible alternative mechanism for the auditory
findings is that increased prenatal lead exposure may
lead to decreased auditory brainstem pathway length.
Rothenberg and colleagues investigated this by using
head circumference as a surrogate measure for pathway
length. They found inverse associations between that
head circumference and prenatal lead level [22]. To test
this alternative hypothesis in our sample, we similarly
analyzed the effects of prenatal lead on head circumfer-
ence. There were no statistically significant differences
in head circumference related to lead level. For visual
acuity, Fox and colleagues have shown that low-level
gestational lead exposure can affect processes in the ret-
ina that do not involve myelination or retinal glial cells,
such as increased neurogenesis of rod photoreceptors
and rod bipolar cells, and decreased retinal dopamine
synthesis, utilization, and release [51]. If low-level prenatal
lead exposure can induce negative effects on the retina,
there is obviously the potential for deficits in visual func-
tion. The Teller Acuity Card procedure used here to assess
grating VA does not allow us to distinguish whether the ob-
served decreases in VA are a result of lead-induced effects
on myelination of the visual pathway, changes in retinal
processes, or some other yet unknown mechanism.
This study is limited by a relatively high LOQ for the
lead measurements. This restricts our ability to use lead
as a continuous variable and to relate variation in lead
levels within the 0–2 μg/dL range to our outcomes of
interest. The clinical significance of our statistically signifi-
cant, but relatively subtle, sensory function deficits early in
infancy is unclear. Additional follow-up throughout infancy
and later in childhood is warranted. Although examiners
were highly trained, assessing very young infants increases
the chances of error, especially for the visual acuity
measurement. Furthermore, solely presenting the TAC
cards in descending order (wider to narrower gratings), as
recommended in the testing manual, may have resulted in
habituation, possibly confounding the acuity estimate.
This can be addressed by presenting the cards in both as-
cending and descending sequence, however limitations in
the attention span of 6-week-old infants necessitated that
the test be completed quickly, thus this was not an option.
Additionally, there may be confounding by iron deficiency
[52], which we addressed in two ways: 1) controlling for
cord blood iron status in our models and 2) performing
sensitivity analyses where infants with low iron stores were
excluded.
This analysis also has a number of strengths. This is
only the fourth study to examine the effects of prenatal
lead exposure on auditory brainstem response in humans
and the first to do so regarding grating visual acuity. The
lead levels in this study are lower than those that have
been examined in the previously published literature, mak-
ing the findings relevant for current day exposure levels.
The tests of sensory function, ABR and grating VA, pro-
vide non-invasive ways of measuring auditory and visual
function in infants, as well as providing insights into the
levels of myelination of those pathways. The collection
of blood lead from three time points during pregnancy
gives a more accurate portrayal of the timing of fetal
lead exposures.
Conclusions
This work provides evidence of delayed auditory and visual
systems maturation in infants with higher prenatal lead ex-
posure during late pregnancy, even at relatively low levels.
Both systems start myelinating in late gestation and mature
rapidly in infancy. Higher ABR C-P ratios and lower grating
VA scores suggest that even low-level lead exposure in late
pregnancy has negative effects on sensory system myelin-
ation early in life.
Visual and auditory system development in infancy
provides the foundation for many subsequent learning
processes, such as communication, language, and reading
development [11, 12]. Therefore, delays or altered timing
of sensory systems myelination with prenatal lead expos-
ure may potentially contribute to poorer developmental
outcomes later on.
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